H. Lundbeck A/S (LON:0ABR)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 4.65B +42.9% |
| Revenue (ttm) | 2.98B +11.2% |
| Net Income | 435.77M +14.5% |
| EPS | 0.44 +14.4% |
| Shares Out | n/a |
| PE Ratio | 10.67 |
| Forward PE | 6.58 |
| Dividend | 0.13 (0.37%) |
| Ex-Dividend Date | Mar 19, 2026 |
| Volume | 2,530 |
| Average Volume | 4,584 |
| Open | 36.90 |
| Previous Close | 35.05 |
| Day's Range | 36.90 - 36.90 |
| 52-Week Range | 25.70 - 39.35 |
| Beta | 0.26 |
| RSI | 52.82 |
| Earnings Date | May 13, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
H. Lundbeck Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue and profit growth, driven by VYEPTI and REXULTI, successful partner market transitions, and pipeline progress. Upgraded guidance reflects robust fundamentals, delayed generic competition, and disciplined capital allocation.
H. Lundbeck Transcript: AGM 2026
Record revenues and profitability were achieved in 2025, with strong growth in strategic brands and a robust pipeline. The board and executive team were re-elected, a new member with neuroscience expertise joined, and all proposals—including a 21% dividend increase—were approved.
Lundbeck price target lowered to DKK 40 from DKK 44 at Deutsche Bank
Deutsche Bank analyst Niall Alexander lowered the firm’s price target on Lundbeck (HLBBF) to DKK 40 from DKK 44 and keeps a Hold rating on the shares. Published first on…
Lundbeck price target lowered to DKK 50 from DKK 53 at Barclays
Barclays lowered the firm’s price target on Lundbeck (HLBBF) to DKK 50 from DKK 53 and keeps an Equal Weight rating on the shares.
H. Lundbeck Transcript: Jefferies Global Healthcare Conference
A focused neuroscience strategy, capital reallocation, and a simplified commercial model have driven strong growth, with VYEPTI and REXULTI as key assets. A diversified, innovation-driven pipeline and dynamic investment approach support upgraded financial guidance and long-term ambitions.
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
H. Lundbeck Earnings Call Transcript: Q3 2025
Double-digit revenue and profit growth in the first nine months of 2025 were driven by Vyepti and Rexulti, leading to upgraded full-year guidance. Strategic pipeline advances and commercial restructuring support long-term growth, despite FX and generic headwinds.
H. Lundbeck Earnings Call Transcript: Q2 2025
Strategic brands drove 21% growth and revenue rose 15% year-over-year, prompting upgraded guidance for both revenue and Adjusted EBITDA. Vyepti and Rexulti led performance, while pipeline and capital reallocation support long-term growth.
H. Lundbeck Earnings Call Transcript: Q1 2025
Q1 2025 saw 16% revenue growth and 24% rise in strategic brands, led by Vyepti and Rexulti. Full-year guidance was raised, reflecting strong demand, robust pipeline progress, and disciplined capital allocation, despite anticipated generic competition and portfolio erosion.
H. Lundbeck Transcript: AGM 2025
The AGM highlighted record financial results, a 36% dividend increase, and a strategic focus on rare neurological diseases through acquisitions and pipeline expansion. All board proposals were adopted, and key risks around R&D and market conditions were discussed with shareholders.
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...